Homeostatic Roles of Eosinophils in Asthma

The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma. The primary objective is to identify eosinophil subpopulations among different groups of severe asthmatic patients using flow cytometry. The study aims to advance understanding of eosinophil diversity, which could guide new therapeutic approaches .

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Asthma; Eosinophilic Eosinophilia Hematologic Diseases Hemic and Lymphatic Diseases Hypereosinophilic Syndrome Leukocyte Disorders Lung Diseases Pulmonary Eosinophilia Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with mild asthma with severe asthma (Biologic-naïve, responders to anti-eosinophil biologic therapies and resistant to anti-eosinophil biologic therapies), control subjects without asthma
Signature of informed consent
Affiliation with the French social security system

Exclusion criteria

Non-eosinophilic asthma
Coexistence of a chronic eosinophilic inflammatory condition other than asthma
Other respiratory conditions (cystic fibrosis, COPD, allergic bronchopulmonary aspergillosis, etc.)
Treatment with corticosteroids within 10 days prior to inclusion
Active smoking or a smoking history of more than 20 pack-years
Pregnant women
Legal incapacity or limited legal capacity
Subject unlikely to cooperate with the study and/or with anticipated low cooperation as assessed by the investigator
Subject without health insurance
Subject currently in an exclusion period of another study or as indicated by the "national registry of volunteers."

Treatment and study plan

Blood Punction

Procedure

venous blood sampling

Primary outcomes

Flow cytometry based eosinophil phenotyping : Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity)

Time frame: at inclusion

Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity)

Study contacts

Contact information is provided by the study sponsor or research team.

Cindy Barnig, MD, PhD

CONTACT

[email protected]

+33 3 81 66 82 04

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Official study title

Characterization of the Homeostatic Functions of Eosinophils in Asthma: An Exploratory Study

Acronym: HOMEOS

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2027
First posted: Nov 6, 2024
Registry last updated: Nov 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting